-
Corporate History
InGeneron, Inc. was formed to develop and adapt advanced separation technologies for cell separation and cell diagnostics, particularly in the emerging field of cell therapy. Bringing together expertise in corporate management and guidance, biology and biotechnology, cell therapy, pharmaceuticals, product development and regulatory affairs, InGeneron is moving the ability to deliver cell therapy from the lab to the bedside.
InGeneron, Inc. is a privately held company, developing its own products for multiple markets, and expanding its reach through both in- and out-licensing agreements.
Work with us
See vacancy
Experience and Track Record
InGeneron, Inc. has collaborated with scientists and research partners for more than 10 years on the use of autologous adult stem cells in regenerative medicine. InGeneron and its team of scientists, physicians and vets have published over 40 peer-reviewed studies at renowned academic facilities such as M.D. Anderson Cancer Center and Tulane University.
Stem Cell Therapy
Innovating Regenerative Medicine™Know-How
InGeneron’s experience has evolved and contributed to the design and development of a point-of-use tissue processing system that efficiently isolates stem and regenerative cells from adipose (fat) tissue. These cells have the potential of differentiating into multiple lineages as well as the capacity to replace damage tissue.
In addition to their regenerative potential, stem regenerative cells serve immune modulatory functions and act as strong anti-inflammatory agents at the site of injury. InGeneron’s process yields a very high number of cells that meet the definition for mesenchymal stem cells stipulated by the International Society for Cellular Therapy.
Newsletter
-
Management
Michael Coleman, Ph.D. has more that 12 years of research management and product development experience in the Biotechnology Industry. Before joining, InGeneron Dr. Coleman held various positions with GeneMedicine, Inc and the successor company Valentis, Inc.
In January 2003 he joined Centelion, SAS, a subsidiary of Sanofi-Aventis, as VP of R&D. Dr. Coleman joined InGeneron, Inc as President and CEO in June 2006.
Over his career, Dr. Coleman has authored or co-authored more than 25 publications in refereed journals and directly managed the preclinical development of multiple drugs that successfully transitioned to the clinical development phase in cardiovascular and oncology indications. Dr. Coleman received his BS and MS from Texas A&M University and his PhD from The Pennsylvania State University. He did postdoctoral work in the Department of Cell Biology at Baylor College of Medicine.
Ron Stubbers is VP of Operations for InGeneron, Inc. focusing on the company’s product development, engineering and regulatory activities. Mr. Stubbers has over 20 years of experience as VP of Operations, VP of Engineering and Manager of Quality and Regulatory Affairs for such companies as Neuroscan, Inc., Compumedics, USA, and aDEPtas, Inc., and was a Director for Neuroscan, Inc.
Serving in various management capacities, he has created, managed and sourced Product Development, Design and Manufacturing Engineering, Quality, Regulatory Affairs, IT, Technical Support, and Materials and Manufacturing activities for those companies, helping to build them into larger companies or transition them through mergers and acquisition.
Jonathan Davis is Director of Sales & Marketing for InGeneron, Inc. and possesses years of experience marketing in the medical field with particular emphases on the launch of new products and the creation of marketing campaigns designed to penetrate large-scale markets.
-
Board of Directors
Eckhard Alt, MD PhD has been Chairman of the Board of InGeneron, Inc since 2006.
Dr. Alt is also Chairman of the Board of MediaCS, Inc located in Houston, TX and since 2001 he has been the Chairman of the Supervisory Board of the Isar Klinik II AG in Munich, Germany. Dr. Alt was the past Chairman of the Supervisory Board of InFlow Dynamics AG, and he has served as a consultant to EP Med Systems, Inc, Guidant, Inc, Intermedics, Inc, and Medtronic, Inc. He has held leadership positions in numerous medical societies including the Advisory Panel for the World Medical Association, and being a founding member of the European Heart Rhythm Association and the European Cardiac Arrhythmia Society.
He is an active researcher and a prolific inventor, holding more than 600 patents worldwide.
Dr. Alt currently holds the position of Professor in the Department of Molecular Pathology at the University of Texas MD Anderson Cancer Center. In addition, Dr Alt holds appointments as Professor of Medicine and Adjunct Professor of Biomedical Engineering at Tulane University Health Science Center and Professor of Medicine at Technische Universitaet in Munich Germany.
Dr. Alt received his MD, graduating at the top of his class, from the University of Heidelberg in Germany.
Jerry C. Griffin,is president of Griffin & Schwartz, Scientific Services, Inc. a management consulting firm in the healthcare products field. Dr. Griffin has assisted several development stage companies in areas ranging from venture and public financing to FDA and clinical trial strategy.
In addition, he is currently a member of the Boards of Directors of 2 public and 4 private companies. During his academic tenure, he held leadership positions in several national and international cardiology organizations and is the author or co-author of 5 books, 4 patents, and over 170 medical and scientific articles.
Bobby I. Griffin retired from a 25 year career with Medtronic, Inc., where he held various positions, including Executive Vice President from 1985 to 1998 and President of Medtronic's Pacemaker Business from 1991 to 1998.
Since his retirement, Mr. Griffin has been a private investor, managing his own fund of companies as well as serving on the advisory boards of Affinity Capital Management Fund III and IV and Sapient Capital Management Fund, in which he also invests.
In addition, Mr. Griffin has served on the Board of Directors of several public companies, including MTS Systems Corporation and Urologix, Inc., and is currently a director of several private companies.
-
Advisory Committee
Edwin K. Hunter practices law in Texas, Louisiana and the District of Columbia.
He graduated from the LSU Law Center where he was a member of Order of the Coif and an editor of the Louisiana Law Review. Edwin has served as chairman of the Louisiana State Bar Association’s Section on Taxation and the Board of Specialization.
He is a director of Ascension Orthopedics, Inc, a co-manager of Mountain Brook Water Company, LLC and a trustee of the Joe W. and Dorothy Dorsett Brown Foundation, the Fritz Lang Foundation, the Olive Tupper Foundation and the Chambers Medical Foundation.
FDA Center for Devices and Radiological Health
FDA Center for Biologics Evaluation and Research
National Institutes of Health Resource for Stem Cell Research
International Federation of Adipose Therapeutics and Science
-
Products
-
ARC™ System
Veterinary
See details -
Transpose RT™ System
Human Clinical
See details -
Matrase™ Enzyme Blend
See details -
ARC™ PRP Kit
See details
Regenerative Cell Preparation at Point-of-Care
InGeneron, Inc. offers a portfolio of products for the preparation, characterization, and administration of a patient’s own adipose-derived regenerative cells. The product line focuses on point-of-use, providing for preparation and administration of cells within a single procedure, in the clinic or out in the field
-
-
What are Regenerative Cells?
Regenerative cells promote healing and regeneration of injured or damaged tissue. Stem cells are regenerative cells that can differentiate into multiple cell types to form new functional tissue. Regenerative cells may also secrete factors that reduce auto-immune responses and inflammation, promote cell survival, and stimulate tissue regeneration. Regenerative cells can be isolated, concentrated, and used therapeutically to repair and regenerate tissue throughout the body. Adipose tissue (fat) is a rich and easily accessible source of regenerative cells.
Applications of Regenerative Cell Therapy
Excess adipose tissue is easily harvested and contains a much higher proportion of regenerative cell types such as mesenchymal stem cells compared to other tissue sources such as bone marrow or blood. Adipose-Derived Regenerative Cells (ADRC's) can be prepared within 90 minutes and administered intravenously or locally to reduce inflammation and promote tissue healing. ADRC can also be used in combination with surgical procedures such as those to repair broken bones or injured tendons and ligaments to enhace the rate and extent of healing.
Platelet Rich Plasma (PRP)
Platelets contain many factors that promote tissue regeneration. These factors are naturally released to promote healing when platelets form a clot such as occurs after injury. This natural reservoir of regenerative factors can easily be harvested from a small sample of a veterinary patient’s own blood in the form of Platelet Rich Plasma (PRP). PRP can be administered to the veterinary patient alone or in combination with ADRC.
InGeneron’s ARC™ System
Enables veterinarians to rapidly prepare PRP from blood and ADRC from your pet’s excess adipose tissue for immediate use. The regenerative cells are available when needed and without the cost, complexities, and delays associated with off-site tissue processing or cell culture.
The Process
Matrase™ Enzyme Blend
Regenerative cells in the body are typically not circulating freely in blood but instead are found in association with a connective tissue matrix within tissue. InGeneron’s proprietary Matrase™ Enzyme Blend is used in the ARC™ System Process to gently dissociate regenerative cells from this matrix so that they can be separated from other tissue components and concentrated. The optimized formulation of Matrase™ Enzyme Blend is the result of years of research focused on maximizing viable cell yield within a minimum time frame. The combination of InGeneron’s ARC™ System with Matrase™ Enzyme Blend enables high viable cell yields in less than 90 minutes.
Matrase™ Enzyme Blend is manufactured to strict quality standards ensuring high purity and consistently high performance. Unlike for some other enzyme preparations, no products of mammalian origin are used in the manufacture of Matrase™ Enzyme Blend.
News
Stem cells helping beloved Houston Zoo pig battle arthritis (View)
Tiger and black leopard undergo stem cell treatment for pain (View)
Malayan Tiger and Black Leopard Undergo Treatment for Arthritis Using Stem Cells Prepared (View)
Big cats get special treatment at the Houston Zoo (View)
Bengal tiger survives stem cell transplant in Mexico (View)
Haley (View)
-
Regenerative Cell Therapy
Regenerative cells promote healing and regeneration of injured or damaged tissue. Stem cells are regenerative cells that can differentiate into multiple cell types to form new functional tissue. Regenerative cells help a body heal itself by reducing inflammation, modulating the immune system, and by regenerating injured tissue. Regenerative cells, including stem cells, are normally distributed in blood vessels throughout the body. Generally, these cells remain dormant for long periods of time. When needed by the body, they are released into circulation where they can migrate to distant areas of injury.
Once at the site of injury, the regenerative cells secrete factors that reduce inflammation and modulate the immune system. They promote regeneration of damaged tissue both by helping to protect and revitalize the injured cells and also by producing new tissue such as cartilage.
With age, parts of the body subject to significant wear and tear deplete the local supply of regenerative cells. For example, joints undergo constant abrasion requiring continued replacement of cartilage. Complicating matters, joints do not have a lot of blood vessels making it more difficult for regenerative cells to be transported from other parts of the body to the joints.
A solution is to help the body transport regenerative cells from healthy tissue to an injured area. Regenerative cells, including stem cells can be obtained from a variety of sources in the body. An ideal source may be a patient’s own fat, also known as adipose tissue. Adipose tissue is rich in blood vessels and, as a result, regenerative cells.
Adipose tissue is easily obtained with a minor surgical procedure. A clinician collects a small amount of adipose tissue from a patient. The tissue is processed to release a regenerative cell preparation that includes stem cells. The use of a patient’s own cells (“autologous cells”) eliminates the risk of disease transmission from donors.
Adipose-derived regenerative cells have been shown to form new tissue such as bone, cartilage, and tendon.
Adipose-derived stem cells secrete factors that can prevent cell death resulting from, for example, ischemic injury (e.g., heart attack or stroke)that deprive cells of oxygen.
InGeneron, Inc. offers a portfolio of products for the preparation, characterization, and administration of a patient’s own adipose-derived regenerative cells. The product line focuses on point-of-use, providing for preparation and administration of cells within a single procedure, in the clinic or out in the field.
Successful Story
Yoda is a Doberman Pinscher that suffered from paralysis due to a spinal cord injury. Yoda's quality of life is improved thanks to InGeneron, Inc.
-
Our Address
InGeneron, Inc. is located at 8205 El Rio St. Houston TX 77054Get in Touch
-
Product Overview Details
ARC™ System - Veterinary
The ARC™ System is designed for point-of-care rapid isolation of regenerative cells in veterinary applications. The ARC™ System consists of a tissue processing unit and single use disposables that enable the isolation of autologous stem cells from a veterinary patient’s own adipose (fat) tissue. The ARC™ System offers clinical grade enzyme and disposables developed in parallel with our systems for human use. The ARC™ System can be used by a local veterinarian to help treat orthopedic injuries, degenerative conditions such as osteoarthritis and non-healing wounds in companion and performance animals. The veterinarian obtains adipose tissue from the patient using syringe lipoaspiration or a minor surgical excision and then isolates the regenerative cells using Matrase™ Enzyme Blend, our proprietary blend of pharmaceutical-grade enzymes. We offer products for small animals, horses, and exotic mammals.For veterinary use only.Transpose RT™ System - Human Clinical
The Transpose RT™ System is a rapid point-of-care system for the preparation of autologous regenerative cells from human lipoaspirate. The Transpose RT™ System consists of a tissue processing unit and single use disposables. A physician extracts a small volume (10-40 cc) of adipose tissue using standard liposuction techniques and then transfers the fat to the Transpose RT™ System for the isolation of autologous stem cells. The Transpose RT™ System uses clinical grade components and is registered for human use upon prescription of a physician in Europe, Mexico and many other countries outside of the US (CE Mark). Our proprietary Matrase™ Enzyme Blend is manufactured under contract by a major biopharmaceutical company under current Good Manufacturing Processes (cGMP) and tested by high-performance liquid chromatography (HPLC). In the US, this device is for investigational use only.Matrase™ Enzyme Blend
InGeneron’s proprietary Matrase™ Enzyme Blend gently releases stem and other regenerative cells from fat. The formulation of Matrase™ Enzyme Blend resulted from years of research focused on maximizing viable cell yield within a minimum time frame. The combination of InGeneron’s ARC™ System with Matrase™ Enzyme Blend enables industry leading viable cell yields in as little as 60 minutes. Matrase™ Enzyme Blend is manufactured to strict quality standards under current Good Manufacturing Practices (cGMP) ensuring consistently high performance. Unlike some other enzyme preparations, Matrase™ Enzyme Blend and all components of the Matrase™ Enzyme Blend manufacturing process are mammalian origin free.ARC™ PRP Kit
The ARC™ PRP Kit allows veterinarians to harness the regenerative properties of platelet rich plasma (PRP) using the ARC™ Tissue Processing Unit. Platelets that are rich in growth factors are collected from a small volume(8-16 cc)of the veterinary patient’s whole blood. The resulting platelet rich plasma can then be administered to the veterinary patient alone or in combination with a preparation of adipose-derived regenerative cells. For veterinary use only.
